only with
Zim Laboratories Ltd.
Zim Laboratories
Zim Laboratories Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Small-cap - With a market cap of ₹7.51 Cr.
| EX-Date | Purpose |
|---|---|
| 29 05 2021 | Audited Results |
| 13 08 2021 | Quarterly Results |
| 30 10 2021 | Quarterly Results |
| 31 01 2022 | Quarterly Results |
| 21 05 2022 | Quarterly Results & Audited Results |
| 26 07 2022 | Quarterly Results |
| 12 11 2022 | Quarterly Results & Bonus issue |
| 03 02 2023 | Quarterly Results |
| 19 05 2023 | Audited Results |
| 14 08 2023 | Quarterly Results |
| 01 11 2023 | Quarterly Results |
| 29 01 2024 | Quarterly Results |
| 09 11 2024 | Quarterly Results |
| 10 02 2025 | Quarterly Results |
| 20 05 2025 | Audited Results |
| 07 08 2025 | Quarterly Results |
| 12 11 2025 | Quarterly Results |
| 21 01 2026 | Inter-alia to consider and approve: (1) the proposal for raising of funds by way of issue of one or more instrument/ securities including equity shares, warrants or securities convertible into equity shares of the Company or debt securities by way of rights issue, preferential issue on a private placement basis, qualified institutional placement or through any other methods or combinations thereof as may be considered appropriate, in accordance with applicable laws, and subject to any regulatory/ statutory approvals as may be required. |
| 11 02 2026 | Quarterly Results |
| 19 05 2026 | Audited Results |
| 06 08 2026 | Quarterly Results |
News
Zim Laboratories incorporates wholly owned subsidiary in Republic of Chile
The incorporation of WOS is with an objective of expansion and development of pharmaceutical business in LATAM region
Zim Laboratories informs about disclosure
Zim Laboratories - Quaterly Results
Zim Laboratories reports Profit after tax of Rs -38.74 Mln, in the June 2026 quarter
Zim Laboratories informs about allotment of equity shares
Zim Laboratories informs about analyst meet
Zim Laboratories informs about newspaper advertisements
Zim Laboratories informs about newspaper publication
ZIM Laboratories secures marketing authorization for ‘Dabigatran Etexilate’ in Italy
This authorisation will facilitate faster approvals in other European Union countries as well as the UK
Zim Laboratories - Quaterly Results
Zim Laboratories reports Profit after tax of Rs 32.81 Mln, in the March 2026 quarter
Zim Laboratories informs about acquisition of equity shares of ZIMTAS
ZIM Laboratories invests Rs 89.45 lakh in ZIMTAS
Post investment, the company holds 99.96% of the total share capital of ZIMTAS
Zim Laboratories informs about disclosure
Zim Laboratories informs about proceedings of EGM
Zim Laboratories gets nod to incorporate subsidiary in Chile
The incorporation of Wholly owned subsidiary is with an objective of expansion and development of business in the LATAM region
Zim Laboratories reports Profit after tax of Rs 42.59 Mln, in the December 2025 quarter
Zim Laboratories informs about outcome of board meeting
Zim Laboratories informs about press release
ZIM Laboratories gets CDSCO’s approval for Naproxen plus Esomeprazole Capsules
This approval strengthens ZIM’s presence in the pain management and gastro-protective therapeutic areas
Zim Laboratories informs about conference call
Zim Laboratories reports Profit after tax of Rs 1.16 Mln, in the September 2025 quarter
Zim Laboratories’ arm gets nod for investment of upto AED 4,50,000 in share capital of ZIM Scientific Office L.L.C
The Board of Directors of the company in their meeting held on August 07, 2025, has approved the same
Zim Laboratories - Quaterly Results
Zim Laboratories - Quaterly Results
Zim Laboratories reports Profit after tax of Rs -16.93 Mln, in the June 2025 quarter
ZIM Laboratories gets Marketing Authorization for Tamsulosin Hydrochloride and Dutasteride Capsules in Australia
This achievement aligns with ZIM’s strategy to leverage its development and manufacturing expertise to build a robust pipeline of differentiated generics for global markets
ZIM Laboratories informs about press release
ZIM Laboratories soars on getting marketing authorization for Rizatriptan Benzoate Orally Disintegrating Films
This milestone reflects ZIM’s continued focus on differentiated, technology-driven generics designed to improve treatment adherence and patient experience
ZIM Laboratories gets marketing authorization for Rizatriptan Benzoate Orally Disintegrating Films
This milestone reflects ZIM’s continued focus on differentiated, technology-driven generics designed to improve treatment adherence and patient experience
ZIM Laboratories’ arm completes investment in ZIM Scientific Office
Post investment, the shareholding of the ZIM FZE remains at 100% of the total share capital of ZIM SO
Zim Laboratories informs about updates on acquisition
Zim Laboratories informs about disclosure
Zim Laboratories jumps on completing investment in SIA ZIM Laboratories
Post investment, the shareholding of the company remains at 100% of the total share capital of SIA ZIM Laboratories
Zim Laboratories completes investment in SIA ZIM Laboratories
Post investment, the shareholding of the company remains at 100% of the total share capital of SIA ZIM Laboratories
Zim Laboratories - Quaterly Results
Zim Laboratories - Quaterly Results
Zim Laboratories reports Profit after tax of Rs 54.20 Mln, in the March 2025 quarter
Zim Laboratories informs about outcome of board meeting
ZIM Laboratories inks pact with Globalpharma to commercialize oral thin film products
Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by the company
ZIM Laboratories rises as its arm gets marketing authorization for Dimethyl Fumarate Capsules
This authorisation will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities
ZIM Laboratories’ arm gets marketing authorization for Dimethyl Fumarate Capsules
This authorisation will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities
Zim Laboratories reports Profit after tax of Rs 43.50 Mln, in the December 2024 quarter
Zim Laboratories - Quaterly Results
Zim Laboratories - Quaterly Results
Zim Laboratories informs about closure of trading window
ZIM Laboratories’ arm incorporates subsidiary in Dubai
With this, the newly incorporated subsidiary become step-down subsidiary of the Company
Zim Laboratories - Quaterly Results
Zim Laboratories reports Profit after tax of Rs 12.17 Mln, in the September 2024 quarter
Zim Laboratories - Quaterly Results
ZIM Laboratories soars on getting nod to invest in equity shares of SIA ZIM Laboratories
The Board of Directors in their meeting held on September 30, 2024 have considered and inter alia approved the same
ZIM Laboratories gets nod to invest in equity shares of SIA ZIM Laboratories
The Board of Directors in their meeting held on September 30, 2024 have considered and inter alia approved the same
Zim Laboratories informs about credit rating
Zim Laboratories - Quaterly Results
Zim Laboratories - Quaterly Results
Zim Laboratories reports Profit after tax of Rs 48.30 Mln, in the December 2023 quarter
Zim Laboratories - Quaterly Results
Zim Laboratories informs about details of loss of certificate
Zim Laboratories informs about closure of trading window
Zim Laboratories informs about loss of share certificates
Zim Laboratories submits analyst meet intimation
ZIM Laboratories informs about investor meet
Zim Laboratories informs about analyst meet
Zim Laboratories informs about transcript of earnings conference call
Zim Laboratories - Quaterly Results
Zim Laboratories - Quaterly Results
Zim Laboratories reports Profit after tax of Rs 41.77 Mln, in the September 2023 quarter
Zim Laboratories informs about board meeting
ZIM Laboratories incorporates step-down Subsidiary
The company has received the license from Dubai Multi Commodities Center for commencement of business
Zim Laboratories informs about analyst meet
Zim Laboratories informs about analyst meet
Zim Laboratories informs about analyst meet
Zim Laboratories informs about loss of share certificates
Zim Laboratories informs about transcript of earnings call
Zim Laboratories - Quaterly Results
Zim Laboratories - Quaterly Results
Zim Laboratories reports Profit after tax of Rs -1.43 Mln, in the June 2023 quarter
Zim Laboratories informs about loss of share certificate
Zim Laboratories informs about AGM
ZIM Laboratories to make strategic investments in Australia, MENA region
These initiatives signify the company’s growth plans and its aim to introduce innovative products for expansion across new markets
ZIM Laboratories informs about newspaper advertisements
Zim Laboratories informs about disclosure
Zim Laboratories informs about loss of share certificate
Zim Laboratories informs about details of loss of certificate
Zim Laboratories informs about loss of share certificate
Zim Laboratories reports Profit after tax of Rs 71.40 Mln, in the March 2023 quarter
Zim Laboratories - Quaterly Results
Zim Laboratories - Quaterly Results
Zim Laboratories informs about board meeting
Zim Laboratories informs about issuance of duplicate share certificate
Zim Laboratories informs about details of loss of certificate
ZIM Laboratories’ arm to transfer marketing authorization of Sildenafil 50 mg orally dissolving film
The company’s wholly owned European Subsidiary executed an agreement with one of the European partner for transfer of the marketing authorization
Zim Laboratories informs about loss of share certificate
Zim Laboratories informs about corporate presentation
Zim Laboratories - Quaterly Results
Zim Laboratories - Quaterly Results
Zim Laboratories informs board meeting
Zim Laboratories informs about amendments to memorandum and articles of association
ZIM Laboratories to list on National Stock Exchange
The company is already listed on the BSE since June 2018, will now extend its listing to the NSE